Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency (EXUROC)

18. listopadu 2026 aktualizováno: Kristoffer Rohrberg

EXUROC Bladder Target - LP-184, an Acylfulvene, for PTGR1-positive, DNA Repair-deficient Urothelial Carcinoma. A Phase Ib/II Study of Safety, Tolerability, and Efficacy in Advanced/Metastatic Urothelial Carcinoma

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.

LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.

The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics.

The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment.

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

EXUROC Bladder Target is an investigator-initiated, single-center, open-label, single-arm Phase Ib/II clinical trial evaluating the safety, tolerability, and antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma (UC) selected by PTGR1 positivity and DNA damage repair (DDR) deficiency.

LP-184 is a next-generation semisynthetic acylfulvene that acts as a prodrug requiring intracellular activation by prostaglandin reductase 1 (PTGR1). Following activation, LP-184 induces DNA damage that may be particularly cytotoxic to tumor cells with deficiencies in DNA repair pathways, including nucleotide excision repair (NER) and homologous recombination (HR). Preclinical studies have demonstrated enhanced sensitivity to acylfulvenes in tumors with impaired DNA repair mechanisms, providing the rationale for biomarker-based patient selection.

The study consists of two sequential phases:

Phase Ib: The first part will evaluate the safety and tolerability of LP-184 and determine the recommended Phase II dose (RP2D). A modified 3+3 dose de-escalation design will be applied, starting at 0.39 mg/kg, with predefined lower dose levels of 0.31 mg/kg and 0.25 mg/kg if dose-limiting toxicities (DLTs) occur. Safety and tolerability will be assessed, and dose de-escalation decisions will be based on observed toxicities.

Phase II: The second part will evaluate the antitumor activity of LP-184 at the RP2D using a Simon's two-stage minimax design. A total of 27 patients will contribute to the Phase II evaluation, including eligible patients treated during Phase Ib. The design allows for early termination if insufficient antitumor activity is observed during the first stage.

LP-184 will be administered intravenously on days 1 and 8 of each 21-day cycle. Treatment may continue for up to one year unless disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria occur.

Tumor response will be evaluated using RECIST version 1.1, and treatment-related adverse events will be assessed using CTCAE version 5.0. Quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

The study aims to determine whether selecting patients based on PTGR1 expression and DDR deficiency can identify a population that may benefit from LP-184 treatment, potentially supporting further clinical development of this biomarker-driven therapeutic strategy.

Typ studie

Intervenční

Zápis (Odhadovaný)

39

Fáze

  • Fáze 2
  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

      • Copenhagen, Dánsko, 2100
        • Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, Denmark

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Provide signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
  • Histologically confirmed progressive, advanced (T4b, N+ or M1) urothelial carcinoma (UC)
  • Measurable disease by RECIST 1.1
  • DDR deficiency by local test
  • PTGR1 overexpression as defined by local test
  • ECOG performance status 0-1
  • Minimum age of 18 years
  • Life expectancy > 3 months
  • No prior treatment with acylfulvenes
  • At least one prior line of systemic treatment. Patients ineligible for standard second-line treatment may be considered for inclusion.
  • At least 4 weeks after major surgery or radiotherapy. Short-duration, limited-field radiotherapy for symptom control is allowed until 2 weeks before C1D1.
  • Adequate organ function at screening defined as:
  • Liver Function:

AST*, ALT* ≤3 × ULN or <5 × ULN in cases of documented liver metastases or involvement of the liver in the disease process.

Total serum bilirubin* ≤1.5 × ULN or <5 × ULN if secondary to Gilbert's Syndrome or documented liver metastases or involvement of the liver in the disease process.

•Renal Function: Serum creatinine clearance ≥45 mL/min either measured or calcu-lated using the standard Cockcroft-Gault formula.

•Bone Marrow Function:ANC* ≥1,5 × 10⁹/L. Hemoglobin* ≥5,0 mmol/L (The use of transfusion or other interven-tion to achieve hemoglobin ≥5,0 mmol/L is acceptable. For those pa-tients undergoing RBC transfusion, hemoglobin must be evaluated at least 14 days after the last RBC transfusion).

Platelet count* ≥100 × 10⁹/L (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).

•Blood clotting function: INR* and aPTT* ≤1.5 × ULN. Patients on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for the intended use.

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days of the first dose of LP-184. A woman is of child bearing potential unless she:

  • has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
  • is aged ≥60 years and is amenorrhoeic.
  • is aged <60 years and has been amenorrhoeic for ≥12 months (including no irregular menses or spotting) in the absence of any medication which induces a meno-pausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone.

Women of childbearing potential must use highly effective contraception. Men of reproductive potential must agree to use highly effective contraceptive methods and avoid sperm donation during the study treatment and for 3 months after the last dose of LP-184. A man is of reproductive potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

Regarding brain metastases, based on one of the following:

  • No clinical evidence of brain metastases.
  • Previously treated brain metastases that are either stable for at least 4 weeks since last treatment or progressed since prior local CNS therapy and not requiring imme-diate re-treatment with local therapy.
  • Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible.

Exclusion Criteria:

  • Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anti-cancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184. (Note: low-dose steroids (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.)

  • Any history of retinopathy and/or macular degeneration (without specifications or grades).

  • Infection requiring antibiotics, antivirals, or antifungals within 1 week prior to first dose of study drug. Prophylactic therapy for e.g. urinary tract infections allowed.

  • Hepatitis B and/or hepatitis C infection (determined on baseline hepatitis B and C screen) or known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).

  • Have clinically significant cardiac disease including:

    • New York Heart Association Class IV heart failure.
    • Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184.
    • Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass.
    • Severe aortic stenosis.
    • Uncontrolled arrhythmia.
    • QTc >470 milliseconds by Fridericia criteria.
    • Congenital long QT syndrome, or a QTcF interval >470 ms (average of triplicate ECGs) at screening and on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to a pacemaker.
  • Have clinically significant AEs that have not resolved to baseline or ≤Grade 1 based on NCI-CTCAE prior to first dose of study drug, unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the investigator, e.g. Grade 2 chemotherapy-induced neuropathy, alopecia, or hypothy-roidism from prior immunotherapy treatment).

  • Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation.

  • Pregnant or breastfeeding women, or women of childbearing potential unwilling or unable to comply with contraception requirements.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: LP-184 arm

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.

LP-184 is an investigational semisynthetic acylfulvene administered intravenously on days 1 and 8 of each 21-day cycle. In Phase Ib, the starting dose is 0.39 mg/kg, with predefined dose de-escalation levels of 0.31 mg/kg and 0.25 mg/kg. In Phase II, LP-184 will be administered at the recommended Phase II dose (RP2D) established during Phase Ib. Treatment may continue for up to one year or until disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Dose-Limiting Toxicity
Časové okno: During the first treatment cycle (21 days).

Number and proportion of participants experiencing dose-limiting toxicities (DLTs) associated with LP-184 treatment, assessed according to the protocol-defined DLT criteria and graded using CTCAE version 5.0.

During the first treatment cycle (21 days).
Recommended Phase II Dose (RP2D) of LP-184
Časové okno: During Phase Ib dose evaluation, up to approximately 6 months

Determination of the recommended Phase II dose (RP2D) of LP-184 based on observed dose-limiting toxicities and overall safety and tolerability during Phase Ib.

During Phase Ib dose evaluation, up to approximately 6 months
Objective Response Rate (ORR) According to RECIST Version 1.1
Časové okno: From treatment initiation until disease progression or end of treatment, up to 1 year.

Proportion of participants achieving a complete response (CR) or partial response (PR) as their best overall response, assessed according to RECIST version 1.1.

From treatment initiation until disease progression or end of treatment, up to 1 year.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-Free Survival (PFS)
Časové okno: From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.
Overall Survival (OS)
Časové okno: From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to death from any cause.

From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.
Duration of Response (DoR)
Časové okno: From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, among participants achieving an objective response according to RECIST version 1.1.

From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

30. listopadu 2026

Primární dokončení (Odhadovaný)

1. listopadu 2029

Dokončení studie (Odhadovaný)

1. listopadu 2031

Termíny zápisu do studia

První předloženo

3. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

18. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2026-525808-94-00
  • 2026-525808-94-00 (Ctis)
  • EXUROC Bladder Target (Jiný identifikátor: Rigshospitalet University Hospital, Copenhagen, Denmark)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Individual participant data are not currently planned to be shared with external researchers.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .